Anx-131 Here

Watch for Phase 2 readouts in late 2027. If successful, this will be a $5 billion molecule within five years of launch.

If Phase 2 data holds up, ANX-131 could be the first oral drug for anxiety since the invention of the benzodiazepine in the 1950s.

Wait—a negative modulator for anxiety ? That sounds backwards. Here is the clever biophysics: The GABA-A receptor has many subunits. ANX-131 is highly selective for the α4β3δ subunit.